Newron Pharmaceuticals SpA (NWRN) – Strategy, SWOT and Corporate Finance Report
- Pages: 49
- Published: July 2023
- Report Code: MLPH82486FSA
Newron Pharmaceuticals SpA (NWRN) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company
Key Highlights
Newron Pharmaceuticals SpA (Newron Pharmaceuticals) is a research-based biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed the product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newton's other products in the pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. It operates along with its subsidiaries in the UK, Switzerland, Sweden, and the US. Newron is headquartered in Bresso, Milan, Italy.
Scope
• Detailed information on Newron Pharmaceuticals SpA required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Newron Pharmaceuticals SpA in the form of a SWOT analysis
• An in-depth view of the business model of Newron Pharmaceuticals SpA including a breakdown and examination of key business segments
• News about Newron Pharmaceuticals SpA, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
• Gain understanding of Newron Pharmaceuticals SpA and the factors that influence its strategies.• Track strategic initiatives of the company and latest corporate news and actions.
• Assess Newron Pharmaceuticals SpA as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on Newron Pharmaceuticals SpAs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
AC Immune SA
Nanobiotix SA
Biotie Therapies Ltd
Santhera Pharmaceuticals Holding AG
Pharming Group NV
Silence Therapeutics Plc
Biofrontera AG
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.